TY - JOUR
T1 - Intraductal carcinoma of prostate reporting practice: A survey of expert European uropathologists
AU - Varma, Murali
AU - Egevad, Lars
AU - Algaba, Ferran
AU - Berney, Daniel
AU - Bubendorf, Lukas
AU - Camparo, Philippe
AU - Comperat, Eva
AU - Erbersdobler, Andreas
AU - Griffiths, David
AU - Grobholz, Rainer
AU - Haitel, Andrea
AU - Hulsbergen-Van De Kaa, Christina
AU - Langner, Cord
AU - Loftus, Barbara
AU - Lopez-Beltran, Antonio
AU - Mayer, Nick
AU - Nesi, Gabriella
AU - Oliveira, Pedro
AU - Oxley, Jon
AU - Rioux-Leclercq, Nathalie
AU - Seitz, Gerhard
AU - Shanks, Jonathan
AU - Kristiansen, Glen
PY - 2016/10/1
Y1 - 2016/10/1
N2 - © 2016 Published by the BMJ Publishing Group Limited. Background It is unclear whether the reported variation in the diagnosis of intraductal carcinoma of the prostate (IDC-P) is due to variable interpretation of borderline morphology, use of different diagnostic criteria or both. Aims We sought to determine the degree of variation in the diagnostic criteria and reporting rules for IDC-P in prostate biopsies employed by expert uropathologists. Methods A questionnaire survey was circulated to 23 expert uropathologists from 11 European countries. Results Criteria used for diagnosis of IDC-P included solid intraductal growth (100%), dense cribriform (96%), loose cribriform/micropapillary with nuclear size >6× normal (83%) or comedonecrosis (74%) and dilated ducts >2× normal (39%). 'Nuclear size' was interpreted as nuclear area by 74% and nuclear diameter by 21%. Pure IDC-P in needle biopsies was reported by 100% and Gleason graded by 30%. All would perform immunohistochemistry in such cases to rule out invasive cancer. An IDC-P component associated with invasive cancer would be included in the determination of tumour extent and number of cores involved by 74% and 83%, respectively. 52% would include IDC-P component when grading invasive cancer. 48% would perform immunohistochemistry in solid or cribriform nests with comedonecrosis to exclude IDC-P (17% routinely, 30% if the focus appeared to have basal cells on H and E). 48% graded such foci as Gleason pattern 5 even if immunohistochemistry demonstrated the presence of basal cells. Conclusions There is a need for more clarity in the definition of some of the diagnostic criteria for IDC-P as well as for greater standardisation of IDC-P reporting.
AB - © 2016 Published by the BMJ Publishing Group Limited. Background It is unclear whether the reported variation in the diagnosis of intraductal carcinoma of the prostate (IDC-P) is due to variable interpretation of borderline morphology, use of different diagnostic criteria or both. Aims We sought to determine the degree of variation in the diagnostic criteria and reporting rules for IDC-P in prostate biopsies employed by expert uropathologists. Methods A questionnaire survey was circulated to 23 expert uropathologists from 11 European countries. Results Criteria used for diagnosis of IDC-P included solid intraductal growth (100%), dense cribriform (96%), loose cribriform/micropapillary with nuclear size >6× normal (83%) or comedonecrosis (74%) and dilated ducts >2× normal (39%). 'Nuclear size' was interpreted as nuclear area by 74% and nuclear diameter by 21%. Pure IDC-P in needle biopsies was reported by 100% and Gleason graded by 30%. All would perform immunohistochemistry in such cases to rule out invasive cancer. An IDC-P component associated with invasive cancer would be included in the determination of tumour extent and number of cores involved by 74% and 83%, respectively. 52% would include IDC-P component when grading invasive cancer. 48% would perform immunohistochemistry in solid or cribriform nests with comedonecrosis to exclude IDC-P (17% routinely, 30% if the focus appeared to have basal cells on H and E). 48% graded such foci as Gleason pattern 5 even if immunohistochemistry demonstrated the presence of basal cells. Conclusions There is a need for more clarity in the definition of some of the diagnostic criteria for IDC-P as well as for greater standardisation of IDC-P reporting.
KW - Genitourinary Pathology
KW - Histopathology
KW - Prostate
KW - Uropathology
U2 - 10.1136/jclinpath-2016-203658
DO - 10.1136/jclinpath-2016-203658
M3 - Review article
SN - 0021-9746
VL - 69
SP - 852
EP - 857
JO - Journal of Clinical Pathology
JF - Journal of Clinical Pathology
IS - 10
ER -